Inhibitors of the MITF molecular pathway

US9745261B2 · kind B2 · utility

Assignees

• The General Hospital Corporation · US
• The Broad Institute, Inc. · US
• University of Kansas · US

Inventors

• Patrick Faloon · Cambridge, US
• Warren S. Weiner · Salt Lake City, US
• Robert A. Smith · Jackson, US
• Frank J. Schoenen · Lawrence, US
• David E. Fisher · Newton, US
• Rizwan Haq · Boston, US

Key dates

• Filing date: Jun 10, 2014
• Grant date: Aug 29, 2017
• Expiry date: Jun 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.